drugset / Trial / NCT03773172
Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100) lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).
Timeline
- Start
- 2019-01-31
- Primary completion
- 2020-08-31
- Completion
- 2020-08-31
Outcome
Outcome not reported
Stopped: “Early termination due to COVID-19”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | recombinant human Lecithin Cholesterol Acyl Transferase | Protein / enzyme biologic | 150 mg | Intravenous |